Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$1.26 +5.9%	$1.00	$0.81 ▼ $1.76	$28.15M	0.74	128,986 shs	208,906 shs
FBLG FibroBiologics	$0.72 -3.4%	$0.92	$0.69 ▼ $6.06	$28.54M	-0.8	298,860 shs	238,854 shs
KA Kineta		$0.66	$0.33 ▼ $5.39	$7.04M	0.46	409,478 shs	530,700 shs
KALA KALA BIO	$4.70 +17.5%	$3.82	$2.92 ▼ $11.20	$25.81M	-1.98	96,490 shs	208,044 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	+2.59%	+15.53%	+22.05%	+13.33%	-15.60%
FBLG FibroBiologics	+3.47%	-0.98%	-7.91%	-28.28%	-85.08%
KA Kineta	0.00%	0.00%	0.00%	0.00%	-21.26%
KALA KALA BIO	-0.50%	-4.31%	-0.99%	-39.12%	-18.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENLV Enlivex Therapeutics	3.0718 of 5 stars	3.7	5.0	0.0	0.0	0.0	0.8	0.6
FBLG FibroBiologics	3.027 of 5 stars	3.6	4.0	0.0	0.0	0.6	3.3	0.6
KA Kineta	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	2.4764 of 5 stars	3.5	1.0	0.0	4.4	0.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	693.65% Upside
FBLG FibroBiologics	3.20	Buy	$13.00	1,704.80% Upside
KA Kineta	0.00	N/A	N/A	N/A
KALA KALA BIO	3.00	Buy	$13.50	187.23% Upside

Current Analyst Ratings Breakdown

Latest KA, FBLG, ENLV, and KALA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/15/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/21/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/9/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/4/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/3/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/1/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/1/2025	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$0.08 per share	N/A
KA Kineta	$5.44M	0.00	N/A	N/A	$0.29 per share	0.00
KALA KALA BIO	$3.89M	7.79	N/A	N/A	$2.02 per share	2.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
FBLG FibroBiologics	-$11.16M	-$0.21	N/A	N/A	N/A	N/A	-1,022.04%	-117.56%	8/6/2025 (Estimated)
KA Kineta	-$14.10M	-$1.50	N/A	N/A	N/A	N/A	-1,044.95%	-336.46%	N/A
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)

Latest KA, FBLG, ENLV, and KALA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/13/2025	Q1 2025	FBLG FibroBiologics	-$0.10	-$0.14	-$0.04	-$0.14	N/A	N/A
3/31/2025	Q4 2024	ENLV Enlivex Therapeutics	-$0.16	-$0.23	-$0.07	-$0.23	N/A	N/A
3/31/2025	Q4 2024	FBLG FibroBiologics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
3/28/2025	Q4 2024	KALA KALA BIO	-$2.28	-$1.74	+$0.54	-$1.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
KA Kineta	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENLV Enlivex Therapeutics	N/A	7.20	7.20
FBLG FibroBiologics	N/A	1.14	1.14
KA Kineta	0.05	0.14	0.14
KALA KALA BIO	3.19	1.99	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENLV Enlivex Therapeutics	1.02%
FBLG FibroBiologics	N/A
KA Kineta	30.32%
KALA KALA BIO	24.61%

Insider Ownership

Company	Insider Ownership
ENLV Enlivex Therapeutics	12.28%
FBLG FibroBiologics	20.00%
KA Kineta	23.70%
KALA KALA BIO	8.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
FBLG FibroBiologics	10	38.26 million	30.61 million	N/A
KA Kineta	40	12.25 million	9.35 million	Not Optionable
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable

KA, FBLG, ENLV, and KALA Headlines

Recent News About These Companies

Mary Reumuth Sells 2,850 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

June 5, 2025 | insidertrades.com

KALA BIO to Present at Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | finance.yahoo.com

Chief Minister cancels programme over unauthorised nature of venue

April 20, 2025 | thehindu.com

KALA BIO: Q4 Earnings Snapshot

March 31, 2025 | timesunion.comT

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 31, 2025 | markets.businessinsider.com

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

February 26, 2025 | finance.yahoo.com

Kala Bio announces CEO departure, appoints interim leader

February 12, 2025 | msn.com

KALA BIO, Inc.: KALA BIO Announces Chief Executive Officer Transition

February 12, 2025 | finanznachrichten.de

Kala Bio appoints new interim CEO amid leadership shuffle

February 12, 2025 | msn.com

Kala announces resignation of CEO Iwicki, Bazemore appointed interim CEO

February 12, 2025 | markets.businessinsider.com

Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction

February 12, 2025 | msn.com

KALA BIO Announces Chief Executive Officer Transition

February 12, 2025 | globenewswire.com

KALA stock soars to 52-week high, reaching $8.81

January 29, 2025 | msn.com

Kala Pharmaceuticals files to sell 1.67M shares of common stock for holders

January 24, 2025 | markets.businessinsider.com

KALA BIO, Inc. (NASDAQ:KALA) CFO Sells $13,016.78 in Stock

January 8, 2025 | insidertrades.com

Bros. Advisors Lp Baker Purchases 310,559 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

January 1, 2025 | insidertrades.com

KALA BIO, Inc. Secures $10.75 Million in Private Placement to Advance Clinical Development of KPI-012

December 30, 2024 | quiverquant.comQ

KALA BIO Announces $10,750,000 Private Placement

December 30, 2024 | globenewswire.com

KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

December 16, 2024 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
These 3 Stocks Are Buying Back Billions in Shares
By Leo Miller | June 3, 2025
View These 3 Stocks Are Buying Back Billions in Shares
Is Consumer Discretionary a Dead End? These 3 Stocks Say No
By Nathan Reiff | June 11, 2025
View Is Consumer Discretionary a Dead End? These 3 Stocks Say No
Wall Street Sees More Upside for Dell and HPE
By Leo Miller | June 12, 2025
View Wall Street Sees More Upside for Dell and HPE

KA, FBLG, ENLV, and KALA Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

$1.26 +0.07 (+5.88%)

Closing price 04:00 PM Eastern

Extended Trading

$1.26 +0.00 (+0.40%)

As of 07:55 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

FibroBiologics NASDAQ:FBLG

$0.72 -0.03 (-3.43%)

Closing price 04:00 PM Eastern

Extended Trading

$0.73 +0.01 (+1.35%)

As of 07:59 PM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Kineta NASDAQ:KA

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.

KALA BIO NASDAQ:KALA

$4.70 +0.70 (+17.50%)

Closing price 04:00 PM Eastern

Extended Trading

$4.83 +0.13 (+2.85%)

As of 07:56 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time